A Phase 1 Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Abbott Japan; AbbVie
- 27 Sep 2014 Results data was presented at the 2014 Annual Congress of the European Society for Medical Oncology (ESMO).
- 27 Sep 2014 Results published in an AbbVie Media Release.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History